Table 4.

Demographic and treatment-related risk factors for ED in survivors^#†

	Frequency (%) of survivors with ED†		Relative risk for ED (95% CI)	p-value
Age at MHQ completion
50+ years	8 / 35	(23)	3.47 (1.39–8.69)	0.008
40–49 years	53 / 358	(15)	2.12 (1.10–4.09)	0.02
30–39 years	42 / 448	(9)	1.42 (0.73–2.76)	0.30
20–29 years	11 / 161	(7)	1.00 (referent)	--
Testicular radiation dose
≥10 Gy	5 / 17	(29)	3.55 (1.53–8.24)	0.003
≥4.0 Gy to <10 Gy	5 / 21	(24)	1.45 (0.56–3.78)	0.45
>0 Gy <4.0 Gy	72 / 559	(13)	1.32 (0.89–1.95)	0.17
None	29 / 340	(9)	1.00 (referent)	--
Surgery on spinal cord/sympathetic nerves (records/self-reported)
Yes	6 / 20	(30)	2.87 (1.36–6.05)	0.006
No	105 / 937	(11)	1.00 (referent)	--
Prostate surgery (records/self-reported)^
Yes	7 /10	(70)	6.56 (3.84–11.20)	<0.0001
No	104 / 947	(11)	1.00 (referent)	--
Pelvic surgery (self-reported)
Yes	7 / 21	(33)	2.28 (1.04–4.98)	0.04
No	103 / 956	(11)	1.00 (referent)	--

^#Only cancer treatment factors and basic demographic characteristics were considered in this model. Health status variables assessed at time of the Men’s Health Questionnaire (e.g. general health) were not included in the treatment factors model because they may themselves be downstream consequences of treatment factors.

^†For analyses assessing the impact of treatments received for primary cancer, subjects who experienced a recurrence or second malignant neoplasm were excluded.

^{^}Biopsies or other diagnostic procedures not included

ED=erectile dysfunction; IIEF-EF = International Index of Erectile Function (Erectile Function Domain)